

Therapeutic Targets for Autoimmune Diseases

- Covering Immune Cell Targets, Cytokines, and Kinases
- High Purity and High Activity

Learn More

The Journal of Immunology

RESEARCH ARTICLE | DECEMBER 01 1980

Studies on the allergenic significance and structure of rat serum albumin.

FREE

U Wahn; ... et. al

J Immunol (1980) 125 (6): 2544–2549.

<https://doi.org/10.4049/jimmunol.125.6.2544>

Related Content

Serological and Cellular Kinetics of the Antibody Light Chain Response to Influenza A and B Viruses in Ferrets

J Immunol (May,2024)

Determining the extent to which clinically effective treatment, ustekinumab or etanercept, reverses the molecular disease profile of psoriatic skin: comparisons of lesional, non-lesional and normal skin (34.5)

J Immunol (April,2010)

Allergens of Mammalian Origin: III. Properties of a Major Feline Allergen

J Immunol (December,1974)

STUDIES ON THE ALLERGENIC SIGNIFICANCE AND STRUCTURE OF RAT SERUM ALBUMIN

ULRICH WAHN,¹ THEODORE PETERS, JR., AND REUBEN P. SIRAGANIAN²

From The Clinical Immunology Section, Laboratory of Microbiology and Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20205; and The Mary Imogene Bassett Hospital, Cooperstown, NY

This study evaluated the capacity of rat serum albumin and of its proteolytic fragments to activate human basophils for IgE-mediated histamine release. The leukocytes from 8 out of 33 patients allergic to rats released histamine with rat serum albumin. Two proteolytic fragments of rat serum albumin, each constituting half of the molecule, were used to study the IgE-reactive antigenic sites. These fragments released histamine with the cells of some of the donors, thus demonstrating the presence of at least 2 antigenic determinants on each fragment for a total minimum of 4 sites on the intact rat serum albumin molecule. Most of the allergenic activity, however, was not recovered in the 2 fragments (total recovery \bar{x} = 6.4%, range between 0.1 and 31%). This loss could be due to cleavage of the rat albumin molecule in the middle of the third domain with loss of antigenic sites and/or due to minor conformational changes in the fragments as compared with the intact molecule. There was up to a 500-fold difference in the percent of activity recovered in the fragments when tested on cells from different patients. Therefore, there is no single immunodominant site on the molecule equally important for all patients. The cells of all 8 patients also reacted with mouse serum albumin but only 2 with bovine serum albumin. At least 1 determinant on mouse and rat serum albumin is cross-reactive with IgE.

Histamine release from washed basophils is an excellent *in vitro* model for IgE-mediated reactions. These studies usually utilize cells from pollen-sensitive patients and trigger the cells with allergen. Although a number of these protein allergens have been purified, the complete amino acid sequence of only a few has been determined, e.g., ragweed Ra5 (1) and cod allergen M (2). There is, however, very little information about the antigenic sites on these molecules capable of reacting with IgE. For example, 2 subunits of ragweed antigen E have been isolated which retained binding activity with human IgE (3). The cod allergen has been split into 2 large peptides, each capable of mediating some of the biologic activity of the native

molecule (4). Several smaller tryptic fragments have also been isolated that retain some of the allergenic activity (5, 6).

Serum albumin is one of the most abundant proteins, and the complete amino acid sequence of bovine and human albumin is known (7). Although the complete sequence of rat albumin has not yet been determined, the sequence of several fragments has been analyzed (8, 9). The albumins from different species are structurally similar; out of 300 amino acids identified in rat serum albumin (RSA)³, 208 were identical with the amino acids at the same positions in human serum albumin and 198 in bovine serum albumin (9). Structural studies indicate that the albumin molecule consists of 9 separate disulfide-bonded loops connected by peptide links of 11 to 26 residues (7). These loops define 3 domains. Limited proteolytic treatment of native albumin produces large fragments probably due to cleavage of unstructured parts of the molecule (10-13). Such fragments appear to retain much of the conformation they assumed in the intact albumin molecule (14). Two fragments have been isolated and characterized from bovine serum albumin. Each fragment consists of one half of the molecule; together they constitute the entire amino acid sequence of bovine albumin (11, 13). The 2 similar half-molecules prepared from RSA, called RSA-P₁₋₃₀₆ and RSA-P₃₀₇₋₅₈₁, were used in the present study.

We utilized RSA as a model for studies of the structure-function relationships of an allergen. Patients who are allergic to animals frequently react to the serum proteins of those same animals (15-18). Thus, serum albumin of various mammalian species (e.g., horses, cats, dogs, and mice) is an important allergen in patients allergic to these animals (18-23). We identified reactivity to RSA in about a quarter of rat allergic individuals; the cells of these individuals also reacted to mouse serum albumin (MSA) but rarely to bovine albumin. Therefore, each of these protein molecules should have at least 2 antigenic sites. Evidence is also presented that 1 antigenic determinant on MSA and RSA is recognized by the same IgE antibodies. Two fragments of the RSA, each constituting half the molecule, retained very little of the allergenic activity of the native albumin. There was wide variation in the reactivity of different individuals to the fragments. The data suggest the presence of at least 4 antigenic sites recognized by IgE on the RSA molecules.

MATERIALS AND METHODS

Materials. Rat allergen extract was obtained as an aqueous

³ Abbreviations used in this paper: D₂O, deuterium oxide; MSA, mouse serum albumin; RSA, rat serum albumin; RSA-P₁₋₃₀₆, peptic fragment of rat serum albumin composed of approximately the first 306 residues; RSA-P₃₀₇₋₅₈₁, peptic fragment of rat serum albumin composed of approximately residues 307 to 581; Pipes ACM, Pipes buffered medium containing Ca⁺⁺ and Mg⁺⁺; EDTA, ethylenediaminetetraacetic acid.

Received for publication March 27, 1980.

Accepted for publication August 28, 1980.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by a fellowship from the Deutsche Forschungsgemeinschaft (Wa 409/1). Present address University Kinderklinik, Heidelberg, West Germany.

² Reprint requests to: Dr. Reuben P. Siraganian, National Institutes of Health, Bldg. 10, Room 2B12, Bethesda, MD 20205.

extract in 50% glycerin from Hollister Stier Laboratories, Spokane, WA. This allergen is prepared from the whole pelt of rats. For histamine release experiments, the extract was used after dialysis against phosphate-buffered saline (NaCl 0.15 M, PO₄ 0.02 M, pH 7.4). The deuterium oxide (D₂O) was purchased from Bio-Rad Laboratories, Richmond, CA.

Rat albumin (RSA). RSA was purified by Dr. Richard C. Feldhoff from serum of adult male Sprague-Dawley rats. The albumin was extracted from a trichloroacetic acid precipitate of the serum proteins with ethanol, dialyzed, and further purified by chromatography with DEAE-cellulose (13). Half-cystine was coupled to the thiol group by a previously described procedure (24) to prevent dimerization.

Bovine serum albumin. Bovine albumin was crystalline bovine plasma albumin from Miles Laboratories, Elkhart, IN.

Mouse albumin (MSA). MSA (Fraction V) was obtained from Sigma, St. Louis, MO. Fatty acids were removed by charcoal treatment as described by Chen (25). The albumin was then dialyzed against phosphate-buffered saline and purified by gel chromatography on a BioGel P100 column.

Solutions. A Pipes-buffered (pH 7.4) medium was used containing NaCl 110 mM, KCl 5 mM, NaOH 40 mM, Pipes 25 mM, and 0.03% human serum albumin (Pipes A). To this medium, 2 mM Ca⁺⁺ and 0.5 mM Mg⁺⁺ were added to prepare Pipes ACM used for diluting antigens and cells for the histamine release reaction. Stock EDTA³ solution was 0.1 M, pH 7.2. Media containing D₂O were prepared by substituting D₂O for water in Pipes ACM.

Peptide fragments. The 2 fragments of RSA were prepared by Dr. Richard C. Feldhoff by limited peptic digestion as described for bovine albumin (13). Purity of all fragments was judged to be greater than 98% by electrophoresis on polyacrylamide gel or on cellulose. Their sizes and locations in the albumin molecule were identified by residue numbers and by the number of disulfide loops in each fragment. Fragment RSA-P₁₋₃₀₆ consists of amino acid residues approximately 1 to 306, with the disulfide loops 1 to 5, and has a m.w. of about 35,000; fragment RSA-P₃₀₇₋₅₈₁ consists of amino acid residues approximately 307 to 581, disulfide loops 6 to 9, and has a m.w. of about 31,500.

Clinical evaluation. The patients in this study were seen in the Employee Allergy Clinic at the N.I.H. They developed allergic symptoms upon exposure to rats. Most of the patients also developed symptoms on exposure to several other laboratory animals. Rat allergy was confirmed by history, intracutaneous skin test, and leukocyte histamine release. For skin tests, 0.02 ml of allergen was injected on the upper arm and the reactions were read at 15 min. Skin test grading was based on measurement of the wheal with the use of the following criteria: neg, site no different from a diluent control; 1+, ≤5 mm wheal; 2+, 5 to 10 mm wheal; 3+, 10 to 15 mm wheal without pseudopods; 4+, >15 mm wheal with or without pseudopods or >10 mm wheal with pseudopods. The highest concentration used for skin tests was 100 PNU/ml, and where appropriate, the skin tests were initiated with lower allergen concentrations.

Leukocytes. Blood was collected in plastic syringes and anticoagulated with 0.01 M EDTA, pH 7.2. It was sedimented at room temperature for 60 to 75 min with 2.5 ml of dextran (clinical dextran 6%, in 0.85% NaCl, to which 3% glucose was added) per 10 ml of blood. The upper layer, containing leukocytes, platelets, and plasma, was transferred by pipetting to another plastic tube and then centrifuged at 300 × G for 8 min at 4°C. The pelleted cells were suspended in Pipes A buffer containing 4 mM EDTA and centrifuged at 300 × G for 8 min

at 4°C. The cells were then washed in Pipes A. After centrifugation, the cells were suspended in Pipes ACM buffer.

Histamine release. Histamine release reactions were carried out in 12 × 75 mm plastic tubes; 0.25 ml of Pipes ACM or antigen was added to the tubes in an ice bath, 0.25 ml of the washed leukocytes was then added to all the tubes, and racks were transferred to a 37°C bath. The racks were shaken every 10 min to resuspend the cells. In each experiment, perchloric acid at a final concentration of 3% was added to some samples to obtain the total histamine content of the cells. At the end of 60 min, the tubes were transferred to an ice bath and centrifuged at 1500 rpm (650 × G) for 15 min at 4°C. The supernatants were decanted and assayed for histamine. Peptide fragments were also used as haptens for inhibition of histamine release; washed leukocytes (0.2 ml) in Pipes ACM were incubated with the fragment (0.2 ml) at 37°C for 10 min, and then 0.2 ml of rabbit serum albumin was added and the reaction was allowed to proceed for 60 min. All experiments were repeated at least twice, and in all tests experimental tubes were in duplicate.

Histamine assay. Histamine was assayed by an automated fluorometric technique (26, 27). Calculations were as described previously (28).

Total serum IgE. Determination of total serum IgE was kindly performed by Dr. T. Waldmann, N.I.H. The values are expressed as nanograms per milliliter.

Statistical methods. The means, standard error, and *t*-statistic for 2 means were calculated using a Hewlett-Packard 65 calculator.

RESULTS

RSA as an allergen. Thirty-three patients were identified who developed allergic symptoms on exposure to rats, had positive skin tests with rat pelt extract, and whose leukocytes released histamine on challenge with rat pelt extract. The leukocytes from these patients were tested for histamine release with RSA at concentrations of 0.01 to 10 μg/ml (1.5 × 10⁻¹⁰ M to 1.5 × 10⁻⁷ M). The cells from only 8 out of 33 patients (24%, of rat allergic individuals) released at least >10% and up to 100%, of their histamine with RSA. The summary of the clinical and laboratory information on these patients is shown in Table I. On exposure to rats, 4 of the patients developed hay fever and asthma, 3 developed only hay fever type of symptoms, and 1 patient developed only asthma. Most of the patients had elevated total serum IgE levels.

The 8 patients allergic to RSA were significantly more sensitive to rat pelt extract than the 25 RSA negative subjects on the basis of both skin test and leukocyte histamine release (Table II). The concentration of rat pelt allergen required for 50% histamine release was 15 PNU/ml for the leukocytes from RSA-negative patients vs 1.6 PNU/ml for the RSA-positive patients.

Histamine release with RSA and peptic fragments of the RSA. The leukocytes of all RSA allergic patients were challenged with the RSA and 2 peptic fragments of the molecule, RSA-P₁₋₃₀₆ and RSA-P₃₀₇₋₅₈₁. The dose-response curves of the leukocytes of two patients are shown in Figure 1. The cells from E.S. respond to both peptic fragments of RSA with histamine release (Fig. 1A). Therefore, there are at least 2 separate determinants on each RSA-P₁₋₃₀₆ and RSA-P₃₀₇₋₅₈₁ fragment. Compared with the whole RSA molecule, RSA-P₁₋₃₀₆ had retained 26% activity and RSA-P₃₀₇₋₅₈₁ 5%. The results with the leukocytes of patient L.W. demonstrate that here even more of the original allergenic activity is lost (Fig. 1B). Fragment RSA-P₃₀₇₋₅₈₁ was inactive at concentrations as high as 3 × 10⁻⁷ M,

TABLE I

Clinical data and histamine release results of 8 patients reactive to rat serum albumin

Clinical Data						Total IgE (ng/ml)	Leukocyte Histamine Release (%)					
NR	Pat.	Age/Sex	Hay-fever*	Asthma*	Skin test Rat Pelt**		Rat Pelt Extract (PNU/ml)			Rat Albumin (μ g/ml)		
							1	10	100	0.01	0.1	1
1	C.L.	41/♂	+	-	4+	1857	55	74	74	65	71	68
2	T.O.	24/♂	+	+	3+	558	64	87	50	74	75	55
3	L.R.	27/♀	+	-	4+	698	N.D.	100	100	94	100	70
4	T.S.	39/♂	+	+	4+	595	62	67	82	36	54	45
5	L.W.	31/♂	+	+	3+	221	22	75	75	13	52	66
6	E.S.	48/♂	+	+	4+	387	17	57	59	65	49	30
7	S.Y.	32/♂	-	+	3+	1250	N.D.	54	44	56	67	70
8	S.W.	35/♀	+	-	4+	519	34	72	31	46	71	71

* Symptoms on exposure to rats

** Intradermal skin test with 100 PNU/ml

TABLE II

Skin test and leukocyte histamine release with rat pelt extract in 33 rat allergic patients

Reactivity to Rat Albumin	N	Rat Pelt Extract						
		Intradermal skin test (100 PNU/ml)				Histamine release with ^a		
		<1+	2+	3+	4+	1 PNU/ml	10 PNU/ml	100 PNU/ml
		No. of subjects				%		
Negative ^b	25	0	9	10	6	16 ± 3	47 ± 4	64 ± 4
Positive	8	0	0	3	5	42 ± 9 ^c	76 ± 6 ^c	68 ± 8


^a Histamine release \bar{x} ± SEM.^b Less than 10% histamine release with 10 μ g/ml of RSA (histamine release \bar{x} = 2.1% ± 0.6).^c These values are significantly different than those in the first line (paired *t*-test, *p* = 0.005).

Figure 1. Histamine release by rat serum albumin and fragments RSA-P₃₀₇₋₅₈₁ and RSA-P₁₋₃₀₆ from the leukocytes of two individuals allergic to rats. A, cells from donor E.S.; fragment RSA-P₁₋₃₀₆ had 26%, and fragment RSA-P₃₀₇₋₅₈₁ 5% of the activity of intact rat albumin. B, cells from donor L.W.; both fragments RSA-P₁₋₃₀₆ and RSA-P₃₀₇₋₅₈₁ retained essentially no activity (less than 0.1%).

whereas RSA-P₁₋₃₀₆ has some activity at very high concentrations (about 0.1%, of the activity of RSA).

A summary of the data from the 8 patients sensitive to RSA is shown in Table III. The antigen dose required for 30% histamine release was calculated from the ascending portion of the antigen dose-response curve. The cells from 4 patients released well with RSA but less than 10% with the peptic fragments. The cells from these patients were retested in buffer containing D₂O to enhance the release. It was found that D₂O

shifts the antigen dose-response curve so that RSA was active at lower concentrations and the peptic fragments now released some histamine. The effect of this was to increase the activity estimates of the peptic fragments (data not shown). Therefore, the activities estimated in the peptic fragments are greater than those that would have been determined in the absence of D₂O.

The antigen dose required for 30% histamine release varied more than 100-fold among the different patients. In general, there was more activity recovered in RSA-P₁₋₃₀₆ than in fragment RSA-P₃₀₇₋₅₈₁ (RSA-P₁₋₃₀₆ \bar{x} = 5.0%, ± 8.7%; RSA-P₃₀₇₋₅₈₁ \bar{x} = 1.4% ± 2.1%). The sum of the total antigenic activity recovered in both fragments was low (\bar{x} = 6.4%, range 0.09% to 31%). This indicates that 70 to 99% of the ability of the antigen to trigger basophils was lost by the cleavage of the molecule in the middle of the second domain. The variability in the response of different patients to the fragments is apparent; e.g., there is a 200- to 500-fold difference in the percent of activity recovered in the fragments as tested with the cells of different patients (Table III).

The variation in reactivity of the different patients with the fragments allows estimates to be made of the possible contamination of these fragments with intact RSA. With the RSA-P₁₋₃₀₆ fragment, the least reactivity was 0.09% of RSA; therefore, this is the maximum possible limit of contamination with rat albumin in the RSA-P₁₋₃₀₆ preparation. The RSA-P₃₀₇₋₅₈₁ preparation could contain even less intact RSA; clearly it is less than 0.01%.

Cell desensitization is an operational term that refers to the unresponsiveness of cells to the repetitive addition of an agent. Desensitization occurs when the cells are exposed to an antigen under nonoptimal conditions (e.g., addition of antigen in the absence of Ca⁺⁺). In nonspecific desensitization, cells desensitized with 1 antigen are unresponsive to other IgE-mediated reactions. With human basophils, both antigen-specific and nonspecific desensitization can occur (29). In order to test whether there are unique or homologous antigenic sites along the RSA molecule, desensitization experiments were done with the cells from each of these 8 patients. Cells were preincubated for 60 min at 37°C in the absence of Ca⁺⁺ with the desensitizing antigen (RSA, RSA-P₁₋₃₀₆ or RSA-P₃₀₇₋₅₈₁) at concentrations previously shown to be capable of releasing histamine. The cells were then washed twice and challenged with the nondesensitizing antigens and anti-IgE (data not shown). RSA caused nonspecific desensitization of the cells of all these patients; fragments that released histamine also caused nonspecific desensitization. However, fragment RSA-P₃₀₇₋₅₈₁ did not release histamine or desensitize the cells of 3 of these patients. Therefore,

TABLE III

Histamine release with rat serum albumin, peptic fragments RSA-P₁₋₃₀₆ and RSA-P₃₀₇₋₅₈₁ from the leukocytes of 8 RSA-sensitive patients

Patients No.	Initials	Testing in Presence of D ₂ O %	RSA Histamine Release Ag ₃₀ ^a M	Fragment RSA-P ₍₁₋₃₀₆₎		Fragment RSA-P ₍₃₀₇₋₅₈₁₎		Total Activity in Fragments (% of RSA)
				Histamine release Ag ₃₀ ^a M	% Activity of RSA ^b	Histamine release Ag ₃₀ ^a M	% Activity of RSA ^b	
1	(E.S.)		8.5 × 10 ⁻¹²	3.3 × 10 ⁻¹¹	25.8	1.6 × 10 ⁻¹⁰	5.3	31.1
2	(C.L.)		1.5 × 10 ⁻¹¹	2.8 × 10 ⁻¹⁰	5.4	4.8 × 10 ⁻¹⁰	3.1	8.5
3	(T.O.)		8.5 × 10 ⁻¹²	3.0 × 10 ⁻¹⁰	2.8	3.0 × 10 ⁻¹⁰	2.8	5.6
4	(S.Y.) ^c	20	3.5 × 10 ⁻¹¹	1.2 × 10 ⁻⁹	2.9	1.0 × 10 ⁻⁷	0.04	2.9
5	(T.S.)	25	3.7 × 10 ⁻¹¹	3.0 × 10 ⁻⁹	1.2	6.5 × 10 ⁻⁹	<0.01	1.2
6	(S.W.)	10	3.1 × 10 ⁻¹⁰	3.0 × 10 ⁻⁸	1.0	<10 ⁻⁶	<0.01	1.0
7	(L.R.)		1.0 × 10 ⁻¹²	2.5 × 10 ⁻¹⁰	0.4	1.0 × 10 ⁻⁹	0.1	0.5
8	(L.W.)	20	3.7 × 10 ⁻¹⁰	4.3 × 10 ⁻⁷	0.09	<10 ⁻⁶	<0.01	0.09

^a Ag₃₀ = Antigen dose required for 30% histamine release.

^b Percent activity of RSA = $\frac{\text{Ag}_{30} \text{ for RSA}}{\text{Ag}_{30} \text{ for fragment}} \times 100$.

^c On immunotherapy with rat pelt extract.

the desensitization experiments were not useful for studies of the antigenic sites on RSA.

Previous studies have demonstrated that the 2 halves of the bovine serum albumin, which are similar to RSA-P₁₋₃₀₆ and RSA-P₃₀₇₋₅₈₁, can associate in solution (24, 30). The complex formed has some of the biologic and immunologic activities of intact bovine albumin molecules. Equimolar concentrations of both peptide fragments were mixed at 10⁻⁷ to 10⁻⁹ M and then added to leukocytes (data not shown). All the histamine release induced by mixture of the 2 fragments could be accounted for by the activity of each fragment added separately. Therefore, there was no evidence for the aggregation on the cell surface of the 2 halves of the RSA molecule.

Peptide fragments as haptens. The leukocytes of 3 of the donors did not release histamine with RSA-P₃₀₇₋₅₈₁ at any of the concentrations tested. This peptide therefore was used in inhibiting the release induced by RSA. Leukocytes were preincubated for 10 min with this peptide, and then RSA at an optimal histamine releasing concentration was added to all the tubes. The cells of 2 of the donors demonstrated no haptenic inhibition of RSA-induced release with RSA-P₃₀₇₋₅₈₁. However, there was significant inhibition by the fragment RSA-P₃₀₇₋₅₈₁ from the cells of the third donor (Fig. 2). The molar ratio for

50% inhibition of RSA-albumin induced release is 60:1. The cells of this donor also released with MSA. When the cells were preincubated with RSA-P₃₀₇₋₅₈₁ and then challenged with MSA, there was inhibition of release (Fig. 2). Although a higher molar ratio of the fragment was required to inhibit MSA than RSA release, this antigenic site on RSA and MSA is clearly similar and reacts with the same IgE molecule.

In inhibition studies with the cells of the only patient with low reactivity to RSA-P₁₋₃₀₆, no monovalent haptenic activity could be demonstrated (patient L.W.). These cells, however, release with RSA-P₁₋₃₀₆ at higher concentrations.

Cross-reactivity between rat, mouse, and bovine serum albumins. The leukocytes from all 8 RSA-sensitive patients released histamine with MSA. The dose-response curves with both albumins were similar: 50% histamine release was induced by 8 × 10⁻¹¹ M RSA and 1.5 × 10⁻¹⁰ M MSA (Fig. 3). The leukocytes from 27 out of the 33 patients allergic to rats released histamine with mouse pelt extract. However, the leukocytes from only 2 out of the 8 RSA-allergic patients released histamine with bovine serum albumin. In both cases the concentration of bovine serum albumin for 50% histamine release was 100- to 1000-fold higher than the concentration of the RSA (data not shown).




Figure 2. Inhibition of rat or mouse serum albumin-induced histamine release by the RSA-P₃₀₇₋₅₈₁ fragment. Cells were preincubated with different concentrations of RSA-P₃₀₇₋₅₈₁ fragment for 10 min at 37°C before the addition of either 3.0 × 10⁻¹⁰ M rat serum albumin (○) or 1.5 × 10⁻¹⁰ M mouse serum albumin (□). Histamine release in the absence of RSA-P₃₀₇₋₅₈₁ was 32% with rat serum albumin and 33% with mouse serum albumin.

DISCUSSION

The results indicate that RSA is an allergen for about 25% of rat-allergic individuals. In previous experiments it has been




Figure 3. Comparison of the ability of rat or mouse serum albumin to release histamine from the cells of rat serum albumin sensitive patients. ○, Rat serum albumin; ▽, mouse serum albumin. The values represent mean ± SEM (N = 8).

shown that MSA is 1 of the 2 major allergens in about 30% of mouse-sensitive patients (23). In the present study no fractionation of the rat pelt allergen was attempted, and therefore we cannot speculate on the relative importance of the albumin as an allergen compared with other proteins present in the pelt extracts.

The recognition of RSA as an allergen allowed the testing of fragments of this molecule for their capacity to release histamine. The leukocytes from some patients release histamine with either of 2 proteolytic fragments, each of which constitutes half of the molecule. Release of histamine requires at least the bridging of 2 adjacent IgE molecules (31). Therefore, each of these 2 fragments (RSA-P₁₋₃₀₆ and RSA-P₃₀₇₋₅₈₁) must contain at least 2 antigenic sites. The total number of antigenic sites recognized by human IgE on the molecule appears to be at least 4. Studies with rabbit antibodies to bovine serum albumin indicate at least 6 antigenic sites distributed throughout the whole molecule (32, 33). Some studies have suggested that rabbit sera late after immunization contain antibodies predominantly to the third domain (34). In contrast to the results with rabbit antibodies to bovine albumin, the leukocytes of our patients appear to react more to the amino-terminal portion of the RSA.

The large fragments obtained by limited proteolysis of albumin retain intact disulfide bonds and unaltered amino acid side chains. Therefore, they resemble the native molecule more than fragments prepared by chemical cleavage techniques (7, 14, 24, 30). Proteolytic cleavage occurs at unstructured parts of the molecule and has the effect of breaking the middle domain in half. The low total recovery of allergenic activity in the 2 fragments could be due to several possibilities. The second (middle) domain might have some important antigenic sites that are lost after cleavage. In general, antigenic sites are on the exposed surface of proteins and constitute amino acids either in continuous peptide linkage or spatially adjacent surface residues (35-37). The sites in the second domain would probably be of spatially adjacent amino acids. It is also possible that cleavage of the albumin molecule into 2 halves results in some minor conformational changes in the fragments. Studies by circular dichroic spectroscopy and magnetic osmometry suggest that there is retention of some of the secondary structure but the fragments are not in their native configuration (14, 30). Immunochemical studies with rabbit antibodies to bovine serum albumin indicate that the 2 fragments are capable of binding precipitating anti-native albumin antibodies (32). The complete loss of the tertiary structure of the albumin molecule results in a loss of its reactivity with antibody to native albumin and the appearance of new-antigenic determinants (33, 38). Important functional interaction between the 2 parts of the second domain of bovine albumin has been observed previously (11, 39).

The importance of conformational determinants has been suspected in a number of allergens (40, 41). The treatment of ragweed antigen E with 8 M urea or 1%, sodium dodecyl sulfate to dissociate the noncovalently bound subunits results in a loss of its biologic reactivity (42, 43). In contrast, the allergenic activity of cod allergen M is stable on heating and on treatment with dissociating agents, suggesting that conformational determinants are not important (44). Our results would suggest that conformational determinants are important for the IgE reaction with RSA.

The 2 peptide halves of the albumin molecule associate when mixed at high concentrations (24, 30). The association constant is low (at 22°C, pH 7.4, it is $7.4 \times 10^3 \text{ M}^{-1}$ and $\sim 1.8 \mu\text{M}^{-1}$ at pH

8.6). The fragments mixed at low concentrations did not trigger the basophils although at the cell surface the IgE-molecules could trap the RSA fragments and result in higher localized concentrations than in solution.

There was significant heterogeneity in the response of the 8 RSA-allergic donors to the proteolytic fragments; the amount of activity recovered in fragment RSA-P₁₋₃₀₆ varied from 0.09%, to 26% (over 250-fold difference). The variation in activity recovered in RSA-P₃₀₇₋₅₈₁ was similar. Out of the 8 donors, 2 did not recognize any determinant in RSA-P₃₀₇₋₅₈₁, 1 recognized 1 (haptenic) determinant, and 5 reacted to at least 2 antigenic sites. On repeated testing, the maximum variation with the cells of the same individual was found to be 6-fold. Therefore, these differences cannot be due to experimental error. Clearly, there is no single immunodominant site in the molecule that is important for all these patients. Whether this is true for other allergens is a crucial question for studies of the genetics of the IgE-response.

The leukocytes from all 8 RSA-sensitive patients released histamine with MSA. The dose-response curves were similar. The simplest explanation would be cross-reactivity due to the IgE reacting with similar antigenic sites on both molecules. Evidence for this cross-reactivity was found with the cells of 1 donor by the ability of RSA-P₃₀₇₋₅₈₁ to block MSA-induced histamine release. Surprisingly, despite similarities in the amino acid sequence of rat and bovine albumin, the leukocytes of only 2 out of 8 subjects reacted with bovine serum albumin. However, haptenic fragments of bovine albumin did not inhibit RSA induced release.

Our results indicate the importance of cross-reactivity in the reaction to allergens, the heterogeneity of the IgE immune response to a well-defined protein, and the substantial loss of the allergenic activity of the RSA by cleavage into 2 fragments.

REFERENCES

- Mole, L. E., L. Goodfriend, C. B. Lapkoff, J. M. Kehoe, and J. D. Capra. 1975. The amino acid sequence of ragweed pollen allergen Ra5. *Biochemistry* 14:1216.
- Elsayed, S., and H. Bennich. 1975. The primary structure of allergen M from cod. *Scand. J. Immunol.* 4:203.
- Paull, B. R., G. J. Gleich, and M. Z. Atassi. 1978. Separation of active subunits of ragweed antigen E. *Immunochemistry* 15:199.
- Elsayed, S., K. Aas, K. Sletten, and S. G. O. Johansson. 1972. Tryptic cleavage of a homogenous cod fish allergen and isolation of two active polypeptide fragments. *Immunochemistry* 9:647.
- Elsayed, S., J. Apold, K. Aas, and H. Bennich. 1976. The allergenic structure of allergen M from cod. I. Tryptic peptides of fragment TM 1. *Int. Arch. Allergy Appl. Immunol.* 52:59.
- Elsayed, S., and J. Apold. 1977. Allergenic structure of allergen M from cod. II. Allergenicity of the limited tryptic hydrolysis peptides of fragment TM 2. *Int. Arch. Allergy Appl. Immunol.* 54:171.
- Brown, J. R. 1977. Serum albumin: amino acid sequence. In *Albumin Structure, Function and Uses*. Edited by V. M. Rosenoer, M. Oratz, and M. A. Rothschild. Pergamon Press, Oxford. p. 27.
- Isemura, S., and T. Ikenaka. 1976. Fragmentation of rat serum albumin by cyanogen bromide cleavage and the amino acid sequences of four fragments. *J. Biochem.* 79:1183.
- Isemura, S., and T. Ikenaka. 1978. Amino acid sequences of fragments I and II obtained by cyanogen bromide cleavage of rat serum albumin. *J. Biochem.* 83:35.
- Peters, T. Jr., and C. Hawn. 1967. Isolation of two large peptide fragments from the amino- and carboxy-terminal positions of serum albumin. *J. Biol. Chem.* 242:1566.
- King, T. P. 1973. Limited pepsin digestion of bovine plasma albumin. *Arch. Biochem. Biophys.* 156:509.
- Peters, T. Jr., and R. C. Feldhoff. 1975. Fragments of bovine serum

- albumin produced by limited proteolysis. Isolation and characterization of tryptic fragments. *Biochemistry* 14:3384.
13. Feldhoff, R. C., and T. Peters, Jr. 1975. Fragments of bovine serum albumin produced by limited proteolysis. Isolation and characterization of peptic fragments. *Biochemistry* 14:4508.
 14. Reed R. G., R. C. Feldhoff, O. L. Clute, and T. Peters, Jr. 1975. Fragments of bovine serum albumin produced by limited proteolysis: conformation and ligand binding. *Biochemistry* 14:4578.
 15. Ohman, J. L., Jr., F. C. Lowell, and K. J. Bloch. 1973. Allergens of mammalian origin: characterization of allergen extracted from cat pelts. *J. Allergy Clin. Immunol.* 52:231.
 16. Ohman, J. L., Jr., F. C. Lowell, and K. J. Bloch. 1975. Allergens of mammalian origin. II. Characterization of allergens extracted from rat, mouse, guinea pig, and rabbit pelts. *J. Allergy Clin. Immunol.* 55:16.
 17. Ponterius, G., R. Brandt, E. Hulten, and L. Yman. 1973. Comparative studies on the allergens of horse dandruff and horse serum. *Int. Arch. Allergy Appl. Immunol.* 44:679.
 18. Brandt, R., G. Ponterius, and L. Yman. 1973. The allergens of cat epithelia and cat serum. Comparative studies based on the radioallergosorbent technique (RAST). *Int. Arch. Allergy Appl. Immunol.* 45:447.
 19. Yman, L., R. Brandt, and G. Ponterius. 1973. Serum albumin—an important allergen in dog epithelia extracts. *Int. Arch. Allergy Appl. Immunol.* 44:358.
 20. Levy D. A. 1975. Allergenic activity of proteins from mice. *Int. Arch. Allergy Appl. Immunol.* 49:219.
 21. Lowenstein, H., B. Markussen, and B. Weeke. 1976. Identification of allergens in extracts of horse hair and dandruff by means of crossed radioimmuno-electrophoresis. *Int. Arch. Allergy Appl. Immunol.* 51:38.
 22. Lowenstein, H., B. Markussen, and B. Weeke. 1976. Isolation and partial characterization of three major allergens of horse hair and dandruff. *Int. Arch. Allergy Appl. Immunol.* 51:48.
 23. Siraganian, R. P., and A. L. Sandberg. 1979. Characterization of mouse allergens. *J. Allergy Clin. Immunol.* 63:435.
 24. Reed, R. G., R. C. Feldhoff, and T. Peters, Jr. 1976. Fragments of bovine serum albumin produced by limited proteolysis: complementary behavior of two large fragments. *Biochemistry* 15:5394.
 25. Chen, R. F. 1967. Removal of fatty acids from serum albumin by charcoal treatment. *J. Biol. Chem.* 242:173.
 26. Siraganian, R. P. 1974. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. *Anal. Biochem.* 57:383.
 27. Siraganian, R. P. 1975. Refinements in the automated fluorometric histamine analysis system. *J. Immunol. Meth.* 7:283.
 28. Siraganian, R. P. 1976. Histamine release and assay methods for the study of human allergy. In *Manual of Clinical Immunology*. Edited by N. R. Rose and H. Friedman, American Society for Microbiology. P. 603.
 29. Sobotka, A. K., M. Dembo, B. Goldstein, and L. M. Lichtenstein. 1979. Antigen-specific desensitization of human basophils. *J. Immunol.* 122:511.
 30. Crouch, T. H., and D. W. Kupke. 1980. Magnetic osmometry: association of two peptic fragments from bovine serum albumin at micromolar concentrations. *Biochemistry* 19:191.
 31. Siraganian, R. P., W. A. Hook, and B. B. Levine. 1975. Specific *in vitro* histamine release from basophils by bivalent haptens: evidence for activation by simple bridging of membrane bound antibody. *Immunochemistry* 12:149.
 32. Peters, T., Jr., R. C. Feldhoff, and R. G. Reed. 1977. Immunochemical studies of fragments of bovine serum albumin. *J. Biol. Chem.* 252:8464.
 33. Teale, J. M., and D. C. Benjamin. 1977. Antibody as immunological probe for studying refolding of bovine serum albumin. *J. Biol. Chem.* 252:4521.
 34. Sakata, S., and M. Z. Atassi. 1979. Immunochemistry of serum albumin. V. A time-dependent examination of the antibody response to bovine serum albumin by the activity of its third domain. *Mol. Immunol.* 16:451.
 35. Sela, M. 1969. Antigenicity: some molecular aspects. Synthetic antigens help our understanding of immunological phenomena on a molecular level. *Science* 166:1365.
 36. Atassi, M. Z. 1975. Antigenic structure of myoglobin. The complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins. *Immunochemistry* 12:423.
 37. Atassi, M. Z., and J. A. Smith. 1978. A proposal for the nomenclature of antigenic sites in peptides and proteins. *Immunochemistry* 15:609.
 38. Goetzl, E. J., and J. H. Peters. 1972. Immunologic alterations in bovine serum albumin resulting from partial or complete reduction and alkylation. *J. Immunol.* 108:785.
 39. Taylor, R. P., and J. B. Vatz. 1973. Bovine serum albumin as a catalyst. Accelerated decomposition of a Meisenheimer complex. *J. Am. Chem. Soc.* 95:5819.
 40. Marsh, D. G. 1975. Allergens and the genetics of allergy. In *The Antigens*. Vol. III. Edited by H. Sela. Academic Press, New York, P. 271.
 41. King, T. P. 1976. Chemical and biological properties of some atopic allergens. *Adv. Immunol.* 23:77.
 42. King, T. P., P. S. Norman, and N. Tao. 1974. Chemical modification of the major allergen of ragweed pollen, antigen E. *Immunochemistry* 11:83.
 43. Ishizaka, K., T. Kishimoto, G. DeLespesse, and T. P. King. 1974. Immunogenic properties of modified antigen E. I. Presence of specific determinants for T cells in denatured antigen and polypeptide chains. *J. Immunol.* 113:70.
 44. Elsayed, S., and K. Aas. 1971. Characterization of a major allergen (cod). Observations on effect of denaturation on the allergenic activity. *J. Allergy* 47:283.